Trastuzumab Deruxtecan Versus Ramucirumab-Paclitaxel as Second-Line Therapy for Patients With HER2-Positive Gastric or GEJ Adenocarcinoma
Journal of the National Comprehensive Cancer Network · 2025
DOI: 10.6004/jnccn.2025.7058 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2025. Verfasst von Rob H A Verhoeven und 5 weiteren Autor:innen. Beteiligte Einrichtung: 1Department of Medical Oncology, University of Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Trastuzumab, Immunoconjugates, Antineoplastic Combined Chemotherapy Protocols, Stomach Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Background
The single-arm phase II DESTINY-Gastric02 (DG-02) study investigated trastuzumab deruxtecan (T-DXd) as second-line therapy in Western patients with HER2-positive unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that progressed during or after trastuzumab-based first-line therapy. The aim of the current study was to compare patients in the DG-02 study with a real-world reference group of patients who received ramucirumab and paclitaxel (Ram + Pac) as second-line therapy.
Methods
A total of 71 of 79 patients from DG-02 who had received trastuzumab in the metastatic setting were included. A comparable cohort of patients with HER2-positive esophageal, gastric, or GEJ adenocarcinoma who received trastuzumab in the first-line setting and Ram + Pac in the second-line setting was identified from the Netherlands Cancer Registry (NCR; n=120). Propensity score trimming and propensity score were used to select a reference group for DG-02 from patients in the NCR, based on sex, age, ECOG performance status, primary tumor location, body mass index, renal function, number of metastatic sites, presence of liver metastases, and duration of first-line therapy.
Results
Propensity score trimming led to the exclusion of 12 patients from the DG-02 group and 33 patients from the NCR group. Thereafter, propensity score matching resulted in a balanced group of patients from the NCR (n=78) and the DG-02 trial (n=58). Median overall survival was significantly longer among patients treated with T-DXd (11.6 months; 95% CI, 9.0–20.5) compared with those treated with the Ram + Pac reference regimen (6.2 months; 95% CI, 4.5–10.0; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- 1Department of Medical Oncology, University of Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.
- 2Cancer Treatment and Quality of Life, Cancer Center Amsterdam, Amsterdam, the Netherlands.
- 3Department of Research & Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands.
- 4Divisions of Oncology, Gastroenterology, Hepatology, and Pulmonology, Department of Medicine, University of Leipzig Medical Center, Comprehensive Cancer Center Central Germany, Leipzig, Germany.
- 5Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands.
- 6Daiichi Sankyo Inc., Basking Ridge, NJ.
Zitieren
APA
Verhoeven, R. H. A., Kuijper, S. C., Lordick, F., Slingerland, M., Qin, A., & van Laarhoven, H. W. M. (2025). Trastuzumab Deruxtecan Versus Ramucirumab-Paclitaxel as Second-Line Therapy for Patients With HER2-Positive Gastric or GEJ Adenocarcinoma. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2025.7058
Vancouver
Verhoeven RHA, Kuijper SC, Lordick F, Slingerland M, Qin A, van Laarhoven HWM. Trastuzumab Deruxtecan Versus Ramucirumab-Paclitaxel as Second-Line Therapy for Patients With HER2-Positive Gastric or GEJ Adenocarcinoma. Journal of the National Comprehensive Cancer Network. 2025. doi:10.6004/jnccn.2025.7058
BibTeX
@article{Verhoeven2025,
author = {Verhoeven, Rob H A and Kuijper, Steven C and Lordick, Florian and Slingerland, Marije and Qin, Amy and van Laarhoven, Hanneke W M},
title = {Trastuzumab Deruxtecan Versus Ramucirumab-Paclitaxel as Second-Line Therapy for Patients With HER2-Positive Gastric or GEJ Adenocarcinoma},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2025},
doi = {10.6004/jnccn.2025.7058}
}
EUVIMED